June 2016 Newsletter
IASLC-LCFA Joint Scholarships
The IASLC and the Lung Cancer Foundation of America (LCFA) are proud to announce a Request for Application for the LCFA/IASLC Lori Monroe Scholarship in Translational Lung Cancer Research. The scholarship will fund two lung cancer research grants over two years. Each grant recipient will receive $200,000. The objective of this award is to support research that improves the care of individuals with lung cancers and to reduce the burden of these diseases.
The deadline to apply is June 30, 2016.
IASLC Lung Cancer News Issue #2
The second issue of IASLC Lung Cancer News, IASLC's newest publication, is now available online. This issue features meeting previews and recaps, interviews with industry experts like Paul A. Bunn, Jr, MD, and Richard Pazdur, MD, along with the latest updates on lung cancer screening and tobacco cessation. To read the publication online simply follow this link. Download a PDF of the publication.
IASLC invites readers to submit article ideas, in addition to new content for future “Names and News” columns, to email@example.com. All submissions are subject to review and approval by the magazine’s editor, and selection for publication is not guaranteed.
Plain Packaging Moves Forward in the UK
The United Kingdom's High Court has upheld "plain packaging" regulations for all cigarette products, dismissing an industry challenge. The regulations stipulate that as of May 20, 2016 all cigarette introduced for sale in the United Kingdom (UK) will be required to comply with "plain packaging" regulations. This includes stripping all cigarette packages of their brand's distinctive colors and logos, and adding graphic health warnings over 65 percent of the front and back of product packages. On May 31, New Zealand and Norway also announced that they will adopt plain packaging regulations.
Regional Organizing Committee Application
The application is now available for parties interested in forming a Regional Organizing Committee (ROC) for IASLC's 20th World Conference on Lung Cancer (WCLC), which will take place in Barcelona, Spain in November 2019. The ROC will be composed of 15-20 IASLC members, and will provide regional leadership to help develop the WCLC's scientific program, social events, and overall logistical plan.
Other responsibilities of the ROC include planning onsite workshops, arranging travel grants and awards, and assisting with press releases and marketing efforts. For a full description of the ROC's role and a link to the application, please visit our website.
As a service to our members, we post opportunities related to lung cancer and other thoracic malignancies on our website.
This now includes academic career opportunities. Click here to review post-doctoral and other career opportunities submitted to IASLC. If you have an academic career opportunity, please email it to firstname.lastname@example.org.
We also post opportunities when we receive information from grantors. We currently have three funding opportunities posted:
These opportunities are available to applicants from all countries. Click here to learn more.
Potential Scams and What to Do
We recently discovered potential Internet scams targeting members of our organization. Please make sure to verify the legitimacy of all IASLC-affiliated websites (including designated conference websites) when visiting, particularly before submitting any sensitive personal or financial information. If uncertain about a specific website, look for the presence of official IASLC logos, or simply utilize www.iaslc.org as a portal.
Additionally, we want our members to be vigilant regarding all email communications. If uncertain about a specific email address, make sure to cross-reference it with other emails you’ve received from that address in the past, or refer to https://www.iaslc.org/contact.
Social Media Corner: Connecting the Community
Need a single online source to highlight top journal articles, share important information, enable networking, or help you better understand patient needs and treatment options? Try Twitter.
The Lung Cancer Social Media (#LCSM) community on Twitter creates collaboration between lung cancer clinicians, researchers, health care facilities, patients, caregivers, advocates, nonprofits, government agencies, media, and the industry. Twitter allows us all to share ideas and information, track new treatments and research, develop advocacy, and connect with others.
Participants span the globe, but connect and collaborate in real time to share their common goal of defeating lung cancer. Lung cancer patients say they find new treatment options and physicians by using #LCSM. Health providers say #LCSM helps them better understand patient perspectives.
Biweekly #LCSM Chats (every other Thursday at 8 p.m. ET) address wide-ranging topics such as precision medicine, how to fight the rising cost of care, overcoming hurdles in clinical research, and living well with metastatic disease. Learn more on the #LCSM Chat website at https://lcsmchat.com/lcsm-chat/.
June 2016: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The selected articles will be made available to the public for a limited time upon printing. The articles below from the June issue of the JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
Economic Analysis of First-Line Treatment by Erlotinib in an EGFR Mutated Population with Advanced Non-small Cell Lung Cancers (NSCLC)
There has been tremendous progress in the therapy of NSCLC over the last few years with the development of inhibitors of relevant oncogenic kinases and recently the checkpoint inhibitors. However, the cost of these therapies raises significant concern. In this issue of the journal, Vergnenegre and colleagues present data on the cost-effectiveness of erlotinib therapy in patients with EGFR-mutant lung cancer.
In the second featured manuscript, Peled and colleagues report a provocative study evaluating exhaled breath analysis in the monitoring of response on NSCLC to therapy.
Even as therapeutic advances continue at a rapid pace, supportive care and quality of life issues continue to be important. Weight loss and cancer cachexia continue to be a topic of interest. Sanders and colleagues evaluate the effect of early weight loss in the outcome of patients undergoing chemoradiation in the third featured article.
Finally, Malignant Pleural Mesothelioma (MPM) is a deadly disease that has seen little progress in therapy since the introduction of Pemetrexed in 2003. Prognostic models to enhance outcomes will be very valuable. For the fourth featured article, Pass and colleagues combined MPM plasma biomarkers with validated clinical prognostic indices to determine whether stratification of risk for death in 194 patients with MPM could be improved.
The following articles have been selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with press releases that were released at the time of online publication (Published Ahead of Print). To read more IASLC Press Releases, please visit IASLC Research Articles. These press releases are also announced via social media, so please follow IASLC on Twitter, LinkedIn, and Facebook to stay up to date on the latest scientific topics
Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib, a small-molecule tyrosine kinase inhibitor.
May 11, 2016 | More
IASLC created the 2016 consensus statement on optimizing management of EGFR mutation positive (M+) NSCLC patients.
Gyula Ostoros - Central European Regent
National Koranyi Institute of Pulmonology
IASLC is encouraged by its significant growth in central Europe, where it more than doubled its membership from 2015 to 2016, expanding from 71 members to 158. This growth can be particularly attributed to partnerships with two national societies: the Polish Lung Cancer Group and the Hungarian Respiratory Society. More recently, IASLC welcomed many new radiation oncologist members from Serbia, Croatia, and Romania at its membership booth exhibition at the 2016 ESTRO Annual Meeting.
The special membership rate is an excellent idea because in this region we are focusing on the next WCLC to be held in Vienna, Austria from December 4-7, 2016. The Regents and many societies in central Europe have a strong collaboration with Professor Robert Pirker, the Congress President. There will be a pre-WCLC meeting about the primary prevention of lung cancer, and the plan is to invite a number of lecturers from our region.
Tobacco smoke remains a significant problem in our region. On May 20, the Hungarian National Assembly implemented a total ban of e-cigarettes in public places, along with other regulations which restrict e-cigarettes from sale outside of national tobacco stores.
For more information about the WCLC 2016, please visit: http://wclc2016.iaslc.org/. For more information about developments in Central Europe, please contact Gyula Ostoros (Ostoros, Gyula email@example.com) or Kristin Richeimer, Director of Membership (firstname.lastname@example.org).
Updated 2016 Member Directory Now Online and Printed Directories Mailed!
The option to receive the printed directory at no cost is a benefit of IASLC membership. In addition to the printed and online directory, members can always search the online, real-time directory. Please contact email@example.com with any questions, or if you have any issues with logging into the membership directory.
You can access the 2016 Member Directory online in two ways:
*New* Free Membership for Patients/Survivors
Welcome New IASLC Members through May 26, 2016 (listed by name, then country):
IASLC Kicks Off Series of Patient Advocate Meetings
During her meeting with IASLC staff, Janet gave a presentation titled “Improving Research and Outcomes with Social Media,” which served as an effective overview of the online communities available to patients, providers, and advocates. She also talked about her recent activities working as a full time patient advocate. Following her presentation, Janet and the IASLC staff discussed the many ways that IASLC and its global membership can benefit from patient engagement and improve outcomes for patients diagnosed with thoracic malignancies. If you are interested in learning more about this program please contact Kristin Richeimer.
IASLC WCLC 2016 Patient Advocacy Awards Announced – Open for Submission:
Applicants for the Advocacy Travel Award are required to submit a detailed application, a summary of expected outcomes for attending, and any other supporting documentation required for review by IASLC. The award is open to organizations that could show 501(c)(3) or a similar type of non-profit status, and to individuals not affiliated with an advocacy organization. Click here for more information.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
February 20 - 23 2019Santa Monica, California
April 3 - 5 2019New York, New York
April 10 - 13 2019Geneva, Switzerland